TRANSCEND-CLL-004: lisocabtagene maraleucel in CLL Published 2020-07-16 Download video MP4 360p Recommendations 02:50 What Makes City of Hope Special 13:50 4 Tricks for when doctors gaslight you - Dr. Kaveh LIVE 01:44 The outcomes of patients with AL amyloidosis and end-stage renal disease 01:43 Meet Neurosurgeon Rahul Jandial, M.D., Ph.D. | City of Hope 03:37 Biomarker analysis of luspatercept versus epoetin alfa in LR-MDS in the Phase III COMMANDS study 03:13 Every Patient Counts, Every Story Matters: Nancy and Bennett 00:59 An overview of the most promising upcoming treatments for amyloidosis 02:06 Morning after Rituxan 18:40 Matthew Perry's Death From Ketamine Explained (Is It Safe For You?) 33:22 How Cancer Clinical Trials May Lead to Treatment Breakthroughs 02:34 Results from a single-cell spatial analysis of the renal AL amyloidosis immunome 01:42 Lives Saved, Families Intact: Yuman Fong, M.D. | City of Hope 01:34 Meet Gastroenterologist James L. Lin, M.D. | City of Hope 14:13 Seconds from Cardiac Arrest - Case Study in Hyperkalemia 01:57 Proteome dynamics during normal and malignant hematopoietic stem cell expansion 02:51 City of Hope Rose Parade Float 2014 01:37 A prospective trial of radiation-free chemotherapy in high- and low-risk HL 12:09 City of Hope Improves the Cancer Patient Experience With Salesforce 03:13 3 things to remember when diagnosing patients with MGUS 01:10 Meet Medical Oncologist Houman Fekrazad, M.D. | City of Hope Similar videos 01:12 Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL 03:56 TRANSCEND-CLL-004: liso-cel in CLL 07:52 Dr. Siddiqi on Liso-Cel in the TRANSCEND CLL 004 Study 03:09 Liso-cel induces rapid uMRD: TRANSCEND-CLL-004 update 03:17 TRANSCEND-CLL-004 study update: safety and efficacy of liso-cel in R/R CLL 03:12 Liso-cel in R/R CLL: 24-month follow-up of TRANSCEND-CLL-004 01:07 The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial 06:19 Lisocabtagene maraleucel is efficacious at treating R/R CLL/SLL 01:12 Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL/SLL 01:16 TRANSCEND CLL-004 update from EHA: liso-cel for R/R CLL 03:34 TRANSCEND-CLL-004: pivotal in the FDA approval of liso-cel for R/R CLL 02:32 MRD status after liso-cel in the TRANSCEND-CLL-004 trial 01:29 TRANSCEND-CLL-04: 18-month follow-up of liso-cel for R/R CLL 04:20 Extended follow-up of the TRANSCEND-CLL-004 monotherapy cohort 03:46 TRANSCEND CLL 004 study 03:53 Latest updates on liso-cel for R/R CLL/SLL 01:17 Preliminary results from Phase I trial of liso-cel plus ibrutinib for R/R CLL 00:34 Copy of Dr. Siddiqi on the Safety Profile of Liso-Cel in the TRANSCEND CLL 004 Trial 00:53 Durable Responses Seen With Liso-Cel for Relapsed/Refractory CLL More results